Amicus Therapeutics
FOLD
FOLD was delisted on the 24th of April, 2026.
147 hedge funds and large institutions have $1.76B invested in Amicus Therapeutics in 2015 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 63 increasing their positions, 43 reducing their positions, and 19 closing their positions.
47% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 43
42% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 19
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
9% more capital invested
Capital invested by funds: $1.61B → $1.76B (+$150M)
5% more funds holding
Funds holding: 140 → 147 (+7)
1% less call options, than puts
Call options by funds: $12.8M | Put options by funds: $12.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$39.6M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$31.9M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$28.6M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$27.3M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$26.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$20.2M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$13M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$9.43M |
| 4 |
ACPU
Arrowgrass Capital Partners (US)
Dover,
Delaware
|
-$8.46M |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$5.81M |
FOLD Hedge Fund Activity: Q3 2015 in Review
147 of the 3,583 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q3 2015, worth a combined $1.76B — up 9.4% from $1.61B a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new FOLD positions and 19 closed out — a net gain of 8 holders — while 63 added to existing stakes and 43 trimmed.
The largest buyer was Vanguard Group, adding an estimated $39.6M. The largest seller was Millennium Management, cutting an estimated $20.2M.
- 147 institutional investors held Amicus Therapeutics (FOLD) as of Q3 2015, up from 140 in Q2 2015.
- Funds reported $1.76B of Amicus Therapeutics stock for Q3 2015, up 9.4% quarter-over-quarter.
- 27 funds opened new Amicus Therapeutics positions in Q3 2015 and 19 closed out, a net change of +8 holders.
- The largest Amicus Therapeutics buyer in Q3 2015 was Vanguard Group, an estimated $39.6M added.
- The largest Amicus Therapeutics seller in Q3 2015 was Millennium Management, an estimated $20.2M sold.
Based on aggregated 13F filings for Q3 2015.